Benzodiazepines Not Tied to Higher Dementia Risk in Older Adults
By Lori Solomon HealthDay Reporter
TUESDAY, July 16, 2024 -- Use of benzodiazepines is not associated with increased dementia risk in older adults, according to a study published online July 2 in BMC Medicine.
Ilse vom Hofe, from Erasmus University Medical Center in the Netherlands, and colleagues examined long-term effects of benzodiazepines (anxiolytics or sedative-hypnotics) on neurodegeneration and dementia risk. The analysis included 5,443 cognitively healthy older adults participating in the population-based Rotterdam Study.
The researchers found that 49.5 percent of participants had used benzodiazepines at any time in the 15 years preceding baseline and 12.8 percent were still using at baseline assessment. During 11.2 years of follow-up, use of benzodiazepines was not associated with dementia risk overall versus never use (hazard ratio [HR], 1.06; 95 percent confidence interval [CI], 0.90 to 1.25), irrespective of cumulative dose. Risk estimates trended higher for any use of anxiolytics than for sedative-hypnotics (HR, 1.17 [95 percent CI, 0.96 to 1.41] versus 0.92 [95 percent CI, 0.70 to 1.21]), with the strongest associations for a high cumulative dose of anxiolytics (HR, 1.33; 95 percent CI, 1.04 to 1.71). Current use of benzodiazepines was associated with lower brain volumes of the hippocampus, amygdala, and thalamus cross-sectionally. Longitudinally, benzodiazepine use was associated with accelerated volume loss of the hippocampus and to a lesser extent amygdala.
"Our results indicate that benzodiazepine use may have a subtle, long-term impact on brain health, although we found no evidence of a dose–response relationship," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2024
Read this next
Metformin, SGLT2 Inhibitors Exhibit Significantly Lower Dementia Risk
MONDAY, July 15, 2024 -- Compared with other antidiabetic classes, metformin and sodium glucose co-transporter-2 inhibitors (SGLT2is) exhibit significantly lower dementia risk...
Nightmares in Midlife May Point to Future Cognitive Decline, Dementia
FRIDAY, July 12, 2024 -- Distressing dreams in middle-aged and older adults may indicate a higher risk for future cognitive decline and all-cause dementia, according to a study...
In-Hospital Delirium Increases Risk for Functional Disability, Cognitive Impairment
THURSDAY, July 11, 2024 -- In-hospital delirium among older adults hospitalized for COVID-19 is associated with increased functional disability and cognitive impairment...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.